The name Neurocrine Biosciences, Inc. (NBIX) should be kept on your radar

The closing price of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was $137.83 for the day, down -2.36% from the previous closing price of $141.16. In other words, the price has decreased by -$3.33 from its previous closing price. On the day, 1173803 shares were traded.

Ratios:

Our analysis of NBIX’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 13.30 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 37.93. For the most recent quarter (mrq), Quick Ratio is recorded 2.40 and its Current Ratio is at 2.45. In the meantime, Its Debt-to-Equity ratio is 0.21 whereas as Long-Term Debt/Eq ratio is at 0.12.

On December 12, 2023, Deutsche Bank started tracking the stock assigning a Buy rating and target price of $136.

Insider Transactions:

Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 21 ’24 when Delaet Ingrid sold 5,000 shares for $145.06 per share. The transaction valued at 725,320 led to the insider holds 7,507 shares of the business.

BENEVICH ERIC sold 75,000 shares of NBIX for $10,453,417 on Mar 14 ’24. The Chief Commercial Officer now owns 40,778 shares after completing the transaction at $139.38 per share. On Mar 14 ’24, another insider, MORROW GEORGE J, who serves as the Director of the company, sold 40,000 shares for $139.42 each. As a result, the insider received 5,576,710 and left with 0 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NBIX now has a Market Capitalization of 13.71B and an Enterprise Value of 13.10B. As of this moment, Neurocrine’s Price-to-Earnings (P/E) ratio for their current fiscal year is 56.72, and their Forward P/E ratio for the next fiscal year is 20.24. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.15. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.27 while its Price-to-Book (P/B) ratio in mrq is 6.09. Its current Enterprise Value per Revenue stands at 6.94 whereas that against EBITDA is 36.60.

Stock Price History:

Over the past 52 weeks, NBIX has reached a high of $148.37, while it has fallen to a 52-week low of $89.04. The 50-Day Moving Average of the stock is 137.34, while the 200-Day Moving Average is calculated to be 117.10.

Shares Statistics:

NBIX traded an average of 850.10K shares per day over the past three months and 1.07M shares per day over the past ten days. A total of 98.70M shares are outstanding, with a floating share count of 96.92M. Insiders hold about 2.60% of the company’s shares, while institutions hold 93.26% stake in the company. Shares short for NBIX as of Feb 29, 2024 were 2.18M with a Short Ratio of 2.92, compared to 1.88M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 2.19% and a Short% of Float of 2.54%.

Earnings Estimates

The firm’s stock currently is rated by 18 analysts. On average, analysts expect EPS of $1 for the current quarter, with a high estimate of $1.77 and a low estimate of $0.21, while EPS last year was -$0.79. The consensus estimate for the next quarter is $1.19, with high estimates of $1.67 and low estimates of $0.89.

Analysts are recommending an EPS of between $5.72 and $3.84 for the fiscal current year, implying an average EPS of $4.8. EPS for the following year is $6.29, with 19 analysts recommending between $8.51 and $4.58.

Revenue Estimates

It is expected that $90B in revenue will be generated in the current quarter, according to 25 analysts. It ranges from a high estimate of $546M to a low estimate of $493M. As of the current estimate, Neurocrine Biosciences, Inc.’s year-ago sales were $409.26M, an estimated increase of 25.70% from the year-ago figure. For the next quarter, 23 analysts are estimating revenue of $546.04M, an increase of 22.10% less than the figure of $25.70% in the same quarter last year. There is a high estimate of $591.3M for the next quarter, whereas the lowest estimate is $528M.

A total of 27 analysts have provided revenue estimates for NBIX’s current fiscal year. The highest revenue estimate was $2.32B, while the lowest revenue estimate was $2.14B, resulting in an average revenue estimate of $2.21B. In the same quarter a year ago, actual revenue was $1.89B, up 17.30% from the average estimate. Based on 27 analysts’ estimates, the company’s revenue will be $2.57B in the next fiscal year. The high estimate is $3.78B and the low estimate is $2.26B. The average revenue growth estimate for next year is up 16.30% from the average revenue estimate for this year.

Most Popular

[the_ad id="945"]